In April 2026, the FDA approved Auvelity, a combination of dextromethorphan and bupropion, for the treatment of agitation associated with Alzheimer's disease dementia. It is the first FDA-approved medication for this specific condition that is not an antipsychotic, a meaningful shift for a symptom that has historically had very limited treatment options.
Here is what agitation looks like in Alzheimer's disease, why this approval matters, and what families should understand before bringing it up with a physician. This article is general medical information, not medical advice.
Agitation is widely regarded as one of the hardest symptoms to manage for both the person living with the disease and the family supporting them.
Why This Approval Matters
Agitation in Alzheimer's disease can include restlessness, emotional distress, and physical or verbal aggression, and it is widely regarded as one of the hardest symptoms to manage for both the person living with the disease and the family supporting them. It is also a leading driver of earlier nursing home placement and a major source of caregiver strain.
How Agitation Is Assessed in a Clinical Setting
Physicians typically rely on standardized behavioral scales, most commonly the Cohen-Mansfield Agitation Inventory, to track agitation symptoms over time rather than relying purely on a caregiver's general impression that things have gotten worse. This kind of structured tracking is part of what allowed Auvelity's clinical trials to demonstrate a measurable improvement rather than a subjective one, and it is also a useful tool for families to ask about, since a physician using this kind of structured tracking can show concretely whether a treatment is actually helping.
How Auvelity Is Different From the Antipsychotic Option
Before this approval, the only FDA-approved medication specifically indicated for Alzheimer's agitation was Rexulti, an antipsychotic that carries a boxed warning for increased mortality risk in elderly patients with dementia-related psychosis. Auvelity works differently, targeting NMDA and sigma-1 receptors rather than the dopamine and serotonin pathways typical of antipsychotics, and it does not carry that same antipsychotic-class mortality warning.
That said, Auvelity is not risk-free. It carries its own boxed warning related to suicidality risk, standard for this class of medication, and it can worsen irritability, increase seizure risk at higher doses, and raise blood pressure in some patients.
Worth noting: this article is general medical information, not medical advice. Any decision about starting or changing medication should be made with the prescribing physician.
What the Clinical Trials Showed
The approval was supported by two Phase 3 trials, ADVANCE-1 and ACCORD-2, which measured agitation using a standard clinical scale.
The Evidence Behind the Approval
Auvelity showed a statistically significant improvement in agitation symptoms compared to placebo, and in the second trial, continuing treatment significantly delayed relapse of symptoms compared to stopping. This is meaningful evidence, though it comes from two trials rather than a broad, long-established track record.
Who This Might Be a Fit For
Medication is generally not the first step in managing agitation. Non-drug approaches, including a consistent routine, a calm and familiar environment, and trained caregivers who understand a resident's specific triggers, remain the foundation of agitation management in most care settings. Whether medication makes sense for a specific resident is a conversation for the prescribing physician, who can weigh the full clinical picture.
What Families and Caregivers Should Watch For
If a loved one starts this medication, watch for dizziness, nausea, headache, dry mouth, sweating, or diarrhea, and report any of these to the prescribing physician. Because of the suicidality boxed warning, close monitoring is especially important when the medication is first started or when the dose changes.
The Caregiver Role in a Successful Treatment Trial
Because a person living with advanced Alzheimer's may not reliably report side effects or changes in mood on their own, caregivers play a central role in monitoring how a new medication like this is actually going. Keeping a simple daily log of agitation episodes, their severity, and any new symptoms gives the prescribing physician far more useful information at a follow-up appointment than a general impression that things seem better or worse.
This kind of structured observation also helps distinguish whether a change in behavior is related to the medication itself or to something else entirely, such as an unrelated illness, a change in routine, or a factor like heat that can independently worsen agitation in someone living with dementia. You can read more about how our caregivers track and communicate changes like this on our Why Us page.
Why Non-Drug Strategies Remain Part of the Plan, Even With Medication
Starting a medication like Auvelity does not mean non-drug strategies stop mattering. Consistent routine, a calm and familiar environment, and caregivers who recognize a resident's specific triggers continue to reduce the frequency and intensity of agitation episodes even for residents on medication, and the two approaches generally work best together rather than as alternatives to each other. A care setting that pairs thoughtful daily structure with appropriate medical oversight tends to see better outcomes than either approach used in isolation.
Common Questions Families Ask
Is Auvelity an antipsychotic?
No. It is the first FDA-approved treatment for Alzheimer's agitation that is not an antipsychotic, working through a different mechanism in the brain.
Quick Takeaway
Auvelity offers a genuinely new, non-antipsychotic option for Alzheimer's agitation, but it carries its own risks and works best alongside, not instead of, non-drug approaches to managing agitation.
What was previously the only FDA-approved medication for Alzheimer's agitation?
Rexulti, an antipsychotic that carries a boxed warning for increased mortality risk in elderly patients with dementia-related psychosis.
What are the risks of Auvelity?
It carries a boxed warning for suicidality risk and can cause dizziness, nausea, headache, and other side effects. It may also worsen irritability and increase seizure risk at higher doses.
Should medication be the first step for managing agitation?
Generally not. Non-drug strategies, including routine, environment, and trained caregiving, are typically tried first. Whether medication is appropriate is a decision for the prescribing physician.
How do doctors measure whether a medication like this is actually working?
Many physicians use a standardized scale, such as the Cohen-Mansfield Agitation Inventory, to track agitation symptoms over time, which gives a more concrete picture than a general sense that behavior has improved or worsened.
Does starting Auvelity mean a resident can stop non-drug approaches to managing agitation?
No. Non-drug strategies, including routine, environment, and familiar caregivers, generally continue alongside medication rather than being replaced by it, and the two approaches tend to work best together.
This article is general medical information, not medical advice. Any decision about starting or changing medication should be made with the prescribing physician. If a loved one's agitation is becoming difficult to manage at home, reach out through our Contact Us page or call (951) 900-4326. We are available Monday through Sunday, 8:00 AM to 8:00 PM.
Ask Us About Managing Agitation
Quick takeaway: Auvelity offers a genuinely new, non-antipsychotic option for Alzheimer's agitation, but it works best alongside, not instead of, non-drug approaches.
Talk to Our Team →